Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
exicorilant
- Development stage
- Phase 1
- Lead developer
- Corcept Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Exicorilant is an orally available, selective glucocorticoid receptor (GR) antagonist developed primarily for oncology indications, especially metastatic castration-resistant prostate cancer (mCRPC). It acts as a competitive and reversible full antagonist of the glucocorticoid receptor, inhibiting GR-mediated proliferative and anti-apoptotic gene expression pathways. By blocking GR activity—which can substitute for androgen receptor signaling in resistant prostate cancer—exicorilant may slow tumor growth and overcome resistance to AR-targeted therapies such as enzalutamide. The drug is a small molecule currently in phase 2 clinical trials, most notably studied in combination with enzalutamide for mCRPC. Exicorilant was developed by Corcept Therapeutics[1][2][3][5][8].
- Other names
- exicorilant [INN]exicorilant [USAN]
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on exicorilant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on exicorilant.